NEW YORK, May 9, 2017 /PRNewswire/ --
This morning, Stock-Callers.com takes a closer look at these Medical Laboratories and Research stocks: Organovo Holdings Inc. (NASDAQ: ONVO), DexCom Inc. (NASDAQ: DXCM), Quest Diagnostics Inc. (NYSE: DGX), and Laboratory Corp. of America Holdings (NYSE: LH). These companies are part of the Healthcare sector, which received an "Outperform" rating from Charles Schwab on April 27th, 2017 due to positive factors such as strong financials and the increased need for health care services. Learn more about these stocks by downloading their free report at:
http://stock-callers.com/registration
Organovo
On Monday, shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 549,433 shares. The stock ended the session 0.37% higher at $2.72. The Company's shares are trading 7.62% below their 50-day moving average. Moreover, shares of Organovo, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 42.98.
On May 01st, 2017, Organovo announced a collaboration with the University of Virginia (UVA) to develop 3D bioprinted tissues for volumetric muscle loss injury. The research will take place in the laboratory of George J. Christ, Ph.D., professor of biomedical engineering and orthopaedic surgery at UVA. The free research report on ONVO is available at:
http://stock-callers.com/registration/?symbol=ONVO
DexCom
San Diego, California headquartered DexCom Inc.'s stock closed the day 3.69% lower at $73.40. A total volume of 2.17 million shares was traded, which was above their three months average volume of 937,590 shares. The Company's shares have advanced 22.95% since the start of this year. The stock is trading 6.56% below its 50-day moving average. Additionally, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 41.31.
On May 03rd, 2017, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $95 a share to $90 a share.
On May 04th, 2017, DexCom announced that its G5 Mobile CGM System can now be used with Apple Watches throughout Europe by downloading the latest version of the G5 Mobile App - iOS 1.6. By adding Apple Watch as another display device, Europeans living with diabetes have even more options to view their glucose readings and alerts on Dexcom's G5 Mobile CGM System to help better manage their diabetes. The complimentary report on DXCM can be downloaded at:
http://stock-callers.com/registration/?symbol=DXCM
Quest Diagnostics
Shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 703,163 shares. The stock ended yesterday's trading session 0.09% higher at $107.19. The Company's shares have advanced 9.53% in the past month, 16.06% in the previous three months, and 17.75% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.40% and 19.47%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 78.18.
On April 26th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $110 a share to $115 a share.
On May 01st, 2017, Quest Diagnostics announced that its senior Vice President and Chief Information Officer, Lidia L. Fonseca, has received a 2017 Forbes CIO Innovation Award. The award, presented during the Forbes Innovation Summit on April 24th, 2017, recognizes CIOs of multibillion-dollar companies who have demonstrated the ability to generate value through innovation. Visit us today and download our complete research report on DGX for free at:
http://stock-callers.com/registration/?symbol=DGX
Laboratory Corp. of America
Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' ("LabCorp®") stock finished Monday's session 0.13% lower at $142.19 with a total trading volume of 499,035 shares. The Company's shares have advanced 9.49% over the previous three months and 10.76% since the start of this year. The stock is trading above its 200-day moving average by 4.81%. Additionally, shares of Laboratory Corp., which operates as an independent clinical laboratory company worldwide, have an RSI of 50.73.
On May 04th, 2017, LabCorp® has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services and Catholic Health Initiatives. With the acquisition, LabCorp assumes PAML's ownership interests in several joint ventures: Colorado Laboratory Services, Kentucky Laboratory Services, MountainStar Clinical Laboratories, PACLAB Network Laboratories, and Tri-Cities Laboratory. Get free access to your technical report on LH at:
http://stock-callers.com/registration/?symbol=LH
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
This morning, Stock-Callers.com takes a closer look at these Medical Laboratories and Research stocks: Organovo Holdings Inc. (NASDAQ: ONVO), DexCom Inc. (NASDAQ: DXCM), Quest Diagnostics Inc. (NYSE: DGX), and Laboratory Corp. of America Holdings (NYSE: LH). These companies are part of the Healthcare sector, which received an "Outperform" rating from Charles Schwab on April 27th, 2017 due to positive factors such as strong financials and the increased need for health care services. Learn more about these stocks by downloading their free report at:
Advertisement
http://stock-callers.com/registration
Organovo
On Monday, shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 549,433 shares. The stock ended the session 0.37% higher at $2.72. The Company's shares are trading 7.62% below their 50-day moving average. Moreover, shares of Organovo, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 42.98.
On May 01st, 2017, Organovo announced a collaboration with the University of Virginia (UVA) to develop 3D bioprinted tissues for volumetric muscle loss injury. The research will take place in the laboratory of George J. Christ, Ph.D., professor of biomedical engineering and orthopaedic surgery at UVA. The free research report on ONVO is available at:
http://stock-callers.com/registration/?symbol=ONVO
DexCom
San Diego, California headquartered DexCom Inc.'s stock closed the day 3.69% lower at $73.40. A total volume of 2.17 million shares was traded, which was above their three months average volume of 937,590 shares. The Company's shares have advanced 22.95% since the start of this year. The stock is trading 6.56% below its 50-day moving average. Additionally, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 41.31.
On May 03rd, 2017, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $95 a share to $90 a share.
On May 04th, 2017, DexCom announced that its G5 Mobile CGM System can now be used with Apple Watches throughout Europe by downloading the latest version of the G5 Mobile App - iOS 1.6. By adding Apple Watch as another display device, Europeans living with diabetes have even more options to view their glucose readings and alerts on Dexcom's G5 Mobile CGM System to help better manage their diabetes. The complimentary report on DXCM can be downloaded at:
http://stock-callers.com/registration/?symbol=DXCM
Quest Diagnostics
Shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 703,163 shares. The stock ended yesterday's trading session 0.09% higher at $107.19. The Company's shares have advanced 9.53% in the past month, 16.06% in the previous three months, and 17.75% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.40% and 19.47%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 78.18.
On April 26th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $110 a share to $115 a share.
On May 01st, 2017, Quest Diagnostics announced that its senior Vice President and Chief Information Officer, Lidia L. Fonseca, has received a 2017 Forbes CIO Innovation Award. The award, presented during the Forbes Innovation Summit on April 24th, 2017, recognizes CIOs of multibillion-dollar companies who have demonstrated the ability to generate value through innovation. Visit us today and download our complete research report on DGX for free at:
http://stock-callers.com/registration/?symbol=DGX
Laboratory Corp. of America
Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' ("LabCorp®") stock finished Monday's session 0.13% lower at $142.19 with a total trading volume of 499,035 shares. The Company's shares have advanced 9.49% over the previous three months and 10.76% since the start of this year. The stock is trading above its 200-day moving average by 4.81%. Additionally, shares of Laboratory Corp., which operates as an independent clinical laboratory company worldwide, have an RSI of 50.73.
On May 04th, 2017, LabCorp® has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services and Catholic Health Initiatives. With the acquisition, LabCorp assumes PAML's ownership interests in several joint ventures: Colorado Laboratory Services, Kentucky Laboratory Services, MountainStar Clinical Laboratories, PACLAB Network Laboratories, and Tri-Cities Laboratory. Get free access to your technical report on LH at:
http://stock-callers.com/registration/?symbol=LH
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
